Europe market for anticoccidial drugs is estimated to grow from 205.79 million in 2018 to USD 492.64 Million by 2023 at a CAGR of 2.89%. Coccidiosis, a parasitic infection of the intestinal tract of animals is caused by coccidian protozoa. The disease feasts from one animal to another by any contact with infected faeces or consumption of infected tissue. It infects a wide variety of animals, such as cattle, poultry, pigs and sheep which is effecting the volumes of meat production. To overcome this problem, anticoccidial drugs play an important role in the prevention and treatment of coccidiosis.
The ban on consumption of antibiotics as a source of animal feed and the upsurge in incidences of antibiotic microbes has seen a reduced growth in the antibiotic market, nevertheless the rising incidence of coccidiosis over the preceding 50 years and its control on the overall cost to benefit ratio for the meat industry has improved the anticoccidials drug market. In addition, the growing consumer preferences for healthy diet is increasing the demand for meat proteins. This is further leading to the rise in usage of anticoccidial drugs by farmers, driving the European anticoccidial drugs market. The trend of owning companion animals is a causative to the mounting demand for anticoccidials in developed regions.
The Europe anticoccidial drugs market is classified based on various types of animals and by type of drugs. The animal segment is sub-categorised into swine, fish, poultry, cattle and companion animals. The companion animals segment is further analysed under dogs and cats. The livestock industry is currently enjoying the high growth rate owing to the increasing demand for meat in the European countries. And on the basis of drug type the market is segmented into antibiotic anticoccidials, Ionophore anticoccidials and chemical derivative anticoccidials. Furthermore, on the basis of geography, the European Market is analysed under various regions namely, UK, Spain, Italy, Germany and France.
The major players in the industry are facing various challenges related to microbial resistance build-up to therapeutics and government regulations in European Union. For this reason, many companies prefer to operate in less regulated markets. Some of the key players operating in the market are Bayer Health care, Boehringer Ingelheim Animal Health, Elanco, Merial, Merck Animal Healthcare, Virbac, Zoetis, Ceva Santé Animale, Novartis Animal Healthcare and Smartvet Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Drug Type
5.1.1 Antibiotic anticoccidials
5.1.2 Ionophore anticoccidials
5.1.3 Chemical derivative anticoccidials
5.2 By Animal Type
5.2.1 Poultry
5.2.2 Swine
5.2.3 Fish
5.2.4 Cattle
5.2.5 Companion Animal
6. Geographical Analysis
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Bayer Health care
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Zoetis
8.3 Elanco
8.4 Merck Animal Healthcare
8.5 Virbac
8.6 Ceva Santé Animale
8.7 Boehringer Ingelheim Animal Health
8.8 Novartis Animal Healthcare
8.9 Smartvet Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
